Find clinical trials for Acute Myeloid Leukemia (AML) in Philadelphia, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia

Leukemia

Myelodysplastic Syndromes

Myeloid Leukemia

Recurrence

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Chronic Myelomonocytic Leukemia

Acute Myeloid Leukemia (AML) trials near Philadelphia, PA, USA:

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML hav...

Active, not recruiting

Acute Myeloid Leukemia (AML)

FLT3-mutated Acute Myeloid Leukemia

Drug: Azacitidine

Drug: Venetoclax

Phase 1, Phase 2

Astellas

Philadelphia, Pennsylvania, United States and 19 other locations

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (...

Active, not recruiting

Relapsed/Refractory AML

Relapsed Acute Myeloid Leukemia (AML)

Drug: AUTX-703

Phase 1

Auron Therapeutics, Inc.

Philadelphia, Pennsylvania, United States and 8 other locations

CART123 + Ruxolitinib in Relapsed/Refractory AML

combination with ruxolitinib in patients with relapsed or refractory acute myeloid leukemia (AML). All subjects w...

Active, not recruiting

Relapsed AML

Refractory AML

Drug: Ruxolitinib 5 MG

Biological: CART123 Cells

Phase 1

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML...

Enrolling

Acute Myeloid Leukemia (AML)

Drug: Daunorubicin

Drug: Azacitidine (AZA)

Phase 3

Kura Oncology

Philadelphia, Pennsylvania, United States and 105 other locations

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...

Active, not recruiting

Acute Myeloid Leukemia

Drug: Quizartinib

Drug: Cytarabine

Phase 1, Phase 2

Daiichi Sankyo

Wilmington, Delaware, United States and 26 other locations

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML...

Enrolling

Myeloid Sarcoma

Nucleophosmin 1-mutated Acute Myeloid Leukemia

Drug: Venetoclax

Drug: Cytarabine

Phase 1

Kura Oncology

Philadelphia, Pennsylvania, United States and 43 other locations

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...

Enrolling

Acute Myeloid Leukemia

Drug: Venetoclax

Drug: Fludarabine

Phase 3

PedAL BCU, LLC

Philadelphia, Pennsylvania, United States and 89 other locations

Phase IB/II of CPX-351 for Relapse Prevention in AML

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1...

Enrolling

Acute Myeloid Leukemia (AML) in Remission

Drug: CPX-351

Phase 1, Phase 2